Director of Research and Development at the Center for Stem Cell and Organoid Medicine (CuSTOM) Cincinnati Children`s Hospital and Medical Center, Ohio, United States
Cincinnati Children’s Hospital Medical Center (CCHMC) has a long and successful history of innovative research and development in pediatric diseases. The emerging field of organoids has presented CCHMC it next focus for innovation. Organoids are increasingly used in applications involving drug discovery and development, predictive diagnosis and organoids-based therapies. Advancements in stem cell methods and technology now allow researchers to use organoids to quickly identify potential drug candidates through a ‘Quick win, fast fail’ approach to be used for the treatment of childhood disease. Lowering drug discovery costs associated with these candidates can result in significant time and cost savings. CCHMC and its Center for Stem Cell and Organoid Medicine (CuSTOM) develops, manufactures and delivers stem cell and organoids-based research tools applications and therapies that will improve child health. High content screening and workcell automation are viewed as vital to CCHMC’s work, as they fulfill a need to standardize experimental techniques, provide scalability to ongoing research and permit CGMP production practices required by the US FDA. This talk discusses the life-saving benefits of automation through tangible, peer-reviewed results including the creation of a patient-derived Individual pluripotent stem cell line library, prediction of drug safety using liver organoids, human organoid-based clinical trials and organoid-based predictive diagnostics. New areas of development made possible by the addition of automation include fully-automated organoid screening workflows and the ability to grow and image 3D organoids from single cell suspensions. Through current initiatives and future collaborations, CCHMC looks to drive the field of Organoid and Regenerative Medicine forward not only to benefit pediatrics but the population at large.